These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9398176)

  • 21. Hybrid proteins between Pseudomonas exotoxin A and poliovirus protease 2Apro.
    Novoa I; Feduchi E; Carrasco L
    FEBS Lett; 1994 Nov; 355(1):45-8. PubMed ID: 7957960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of action of Pseudomonas exotoxin. Identification of a rate-limiting step.
    Zdanovsky AG; Chiron M; Pastan I; FitzGerald DJ
    J Biol Chem; 1993 Oct; 268(29):21791-9. PubMed ID: 8408034
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A recombinant form of Pseudomonas exotoxin A containing transforming growth factor alpha near its carboxyl terminus for the treatment of bladder cancer.
    Theuer CP; FitzGerald DJ; Pastan I
    J Urol; 1993 Jun; 149(6):1626-32. PubMed ID: 8501821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies.
    Mansfield E; Pastan I; FitzGerald DJ
    Bioconjug Chem; 1996; 7(5):557-63. PubMed ID: 8889017
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.
    Brinkmann U; Lee BK; Pastan I
    J Immunol; 1993 Apr; 150(7):2774-82. PubMed ID: 8454854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of monoclonal antibody B7, which neutralizes the cytotoxicity of Pseudomonas aeruginosa exotoxin A.
    Shang HF; Yeh ML; Lin CP; Hwang J
    Clin Diagn Lab Immunol; 1996 Nov; 3(6):727-32. PubMed ID: 8914766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds.
    Kreitman RJ; Batra JK; Seetharam S; Chaudhary VK; FitzGerald DJ; Pastan I
    Bioconjug Chem; 1993; 4(2):112-20. PubMed ID: 7873642
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant toxins that bind to the urokinase receptor are cytotoxic without requiring binding to the alpha(2)-macroglobulin receptor.
    Rajagopal V; Kreitman RJ
    J Biol Chem; 2000 Mar; 275(11):7566-73. PubMed ID: 10713063
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Properties of chimeric toxins with two recognition domains: interleukin 6 and transforming growth factor alpha at different locations in Pseudomonas exotoxin.
    Kreitman RJ; Siegall CB; Chaudhary VK; FitzGerald DJ; Pastan I
    Bioconjug Chem; 1992; 3(1):63-8. PubMed ID: 1616951
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotoxins made with a recombinant form of Pseudomonas exotoxin A that do not require proteolysis for activity.
    Theuer CP; Kreitman RJ; FitzGerald DJ; Pastan I
    Cancer Res; 1993 Jan; 53(2):340-7. PubMed ID: 8417828
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story.
    McKee ML; FitzGerald DJ
    Biochemistry; 1999 Dec; 38(50):16507-13. PubMed ID: 10600112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver.
    Chiron MF; Fryling CM; FitzGerald DJ
    J Biol Chem; 1994 Jul; 269(27):18167-76. PubMed ID: 8027078
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant chimeric vaccine composed of PRRSV antigens and truncated Pseudomonas exotoxin A (PE-K13).
    Yang HP; Wang TC; Wang SJ; Chen SP; Wu E; Lai SQ; Chang HW; Liao CW
    Res Vet Sci; 2013 Oct; 95(2):742-51. PubMed ID: 23712024
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant anti-erbB2 immunotoxins containing Pseudomonas exotoxin.
    Batra JK; Kasprzyk PG; Bird RE; Pastan I; King CR
    Proc Natl Acad Sci U S A; 1992 Jul; 89(13):5867-71. PubMed ID: 1352878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
    Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
    J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia.
    Kreitman RJ; Chaudhary VK; Kozak RW; FitzGerald DJ; Waldman TA; Pastan I
    Blood; 1992 Nov; 80(9):2344-52. PubMed ID: 1421405
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
    Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
    Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A target-specific chimeric toxin composed of epidermal growth factor and Pseudomonas exotoxin A with a deletion in its toxin-binding domain.
    Liao CW; Hseu TH; Hwang J
    Appl Microbiol Biotechnol; 1995 Jul; 43(3):498-507. PubMed ID: 7632400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells.
    Du X; Ho M; Pastan I
    J Immunother; 2007 Sep; 30(6):607-13. PubMed ID: 17667524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner.
    Kuan CT; Wang QC; Pastan I
    J Biol Chem; 1994 Mar; 269(10):7610-6. PubMed ID: 8125985
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.